Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hortobagyi, G. N.
Right arrow Articles by Reitsma, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hortobagyi, G. N.
Right arrow Articles by Reitsma, D. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 16, 2038-2044, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

GN Hortobagyi, RL Theriault, A Lipton, L Porter, D Blayney, C Sinoff, H Wheeler, JF Simeone, JJ Seaman, RD Knight, M Heffernan, K Mellars and DJ Reitsma
Department of Breast Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA. ghorto@notes.mdacc.tmc.edu

PURPOSE: Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy. We studied the long-term effectiveness and safety of continued treatment with intravenous pamidronate infusions for up to 2 years. PATIENTS AND METHODS: Three hundred eighty-two women with metastatic breast cancer and lytic bone lesions who received chemotherapy were randomly assigned to receive either 90 mg of pamidronate or placebo intravenously every 3 to 4 weeks in this double- blind, multicenter, parallel-group trial. Patients were evaluated monthly for 2 years for skeletal complications, which included pathologic fractures, need for radiation or surgery to treat bone complications, spinal cord compression, and hypercalcemia. Bone pain, analgesic use, bone biochemical markers, performance status, quality of life, radiologic response in bone, and survival were also evaluated. RESULTS: As in the first year of treatment, the proportion of patients with any skeletal complication was significantly less for the pamidronate than the placebo group at 15, 18, 21, and 24 months (P < .001). The proportions of patients with any pathologic fracture (i.e., vertebral and nonvertebral fractures), need for radiation or surgery to treat bone complications, and hypercalcemia were also statistically less for the pamidronate than the placebo group. The median time to the first skeletal complication was 13.9 months in the pamidronate-treated women and 7.0 months in the placebo group (P < .001). Long-term treatment did not result in any unexpected adverse events. Survival did not differ between the two groups. CONCLUSION: The risk for osteolytic bone lesion complications in metastatic breast cancer was significantly decreased with monthly infusions of 90 mg of pamidronate, and this effect was maintained for at least 2 years. Pamidronate is a useful adjunct to standard chemotherapy in the palliative treatment of metastatic breast cancer.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Beslija, J. Bonneterre, H. J. Burstein, V. Cocquyt, M. Gnant, V. Heinemann, J. Jassem, W. J. Kostler, M. Krainer, S. Menard, et al.
Third consensus on medical treatment of metastatic breast cancer
Ann. Onc., November 1, 2009; 20(11): 1771 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken
Bisphosphonates in Oncology: Rising Stars or Fallen Heroes
Oncologist, February 1, 2009; 14(2): 181 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. T. Drake, B. L. Clarke, and S. Khosla
Bisphosphonates: Mechanism of Action and Role in Clinical Practice
Mayo Clin. Proc., September 1, 2008; 83(9): 1032 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. H. Giordano, S. Fang, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, and J. S. Goodwin
Use of Intravenous Bisphosphonates in Older Women with Breast Cancer
Oncologist, May 1, 2008; 13(5): 494 - 502.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Ann. Onc., March 1, 2008; 19(3): 420 - 432.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
S.L. Ruggiero and S.J. Drew
Osteonecrosis of the Jaws and Bisphosphonate Therapy
Journal of Dental Research, November 1, 2007; 86(11): 1013 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Lipton, G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.-J. Body, R. de Boer, R. Berardi, P. Gascon, K. S. Tonkin, et al.
Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases
J. Clin. Oncol., October 1, 2007; 25(28): 4431 - 4437.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Bergner, D. M. Henrich, M. Hoffmann, A. Honecker, G. Mikus, B. Nauth, D. Nagel, and M. Uppenkamp
Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function
J. Clin. Pharmacol., August 1, 2007; 47(8): 942 - 950.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli
The Use of Bisphosphonates in Elderly Cancer Patients
Oncologist, January 1, 2007; 12(1): 62 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-J. Body
Breast cancer: bisphosphonate therapy for metastatic bone disease.
Clin. Cancer Res., October 15, 2006; 12(20): 6258s - 6263s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Cook and P. Major
Multistate analysis of skeletal events in patients with bone metastases.
Clin. Cancer Res., October 15, 2006; 12(20): 6264s - 6269s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Powles, E. McCroskey, and A. Paterson
Oral bisphosphonates as adjuvant therapy for operable breast cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6301s - 6304s.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon
Emerging anti-cancer molecular mechanisms of aminobisphosphonates.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-J. Body, T. Facon, R. E. Coleman, A. Lipton, F. Geurs, M. Fan, D. Holloway, M. C. Peterson, and P. J. Bekker
A Study of the Biological Receptor Activator of Nuclear Factor-{kappa}B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1221 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bamias, E. Kastritis, C. Bamia, L. A. Moulopoulos, I. Melakopoulos, G. Bozas, V. Koutsoukou, D. Gika, A. Anagnostopoulos, C. Papadimitriou, et al.
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
J. Clin. Oncol., December 1, 2005; 23(34): 8580 - 8587.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, Y. Iino, T. Watanabe, C. Goessl, Y. Ohashi, and S. Takashima
Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial
J. Clin. Oncol., May 20, 2005; 23(15): 3314 - 3321.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. E. Coleman
Bisphosphonates in breast cancer
Ann. Onc., May 1, 2005; 16(5): 687 - 695.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. R. Berenson
Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases
Oncologist, January 1, 2005; 10(1): 52 - 62.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. L. Vogel, R. H. Yanagihara, A. J. Wood, F. M. Schnell, C. Henderson, B. H. Kaplan, M. H. Purdy, R. Orlowski, J. L. Decker, L. Lacerna, et al.
Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy
Oncologist, November 1, 2004; 9(6): 687 - 695.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Mancini, J.-C. Dumon, and J.-J. Body
Efficacy and Safety of Ibandronate in the Treatment of Opioid-Resistant Bone Pain Associated With Metastatic Bone Disease: A Pilot Study
J. Clin. Oncol., September 1, 2004; 22(17): 3587 - 3592.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. E. Coleman
Bisphosphonates: Clinical Experience
Oncologist, September 1, 2004; 9(suppl_4): 14 - 27.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno
Bone Imaging in Metastatic Breast Cancer
J. Clin. Oncol., July 15, 2004; 22(14): 2942 - 2953.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Berenson and R. Hirschberg
Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid
Oncologist, June 1, 2004; 9(3): 319 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Rizzoli
Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer
Ann. Onc., May 1, 2004; 15(5): 700 - 701.
[Full Text] [PDF]

Home page
 Ann OncolHome page
D. Tripathy, M. Lichinitzer, A. Lazarev, S. A. MacLachlan, J. Apffelstaedt, M. Budde, and B. Bergstrom
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial
Ann. Onc., May 1, 2004; 15(5): 743 - 750.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. J. Small, M. R. Smith, J. J. Seaman, S. Petrone, and M. O. Kowalski
Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer
J. Clin. Oncol., December 1, 2003; 21(23): 4277 - 4284.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
H L Neville-Webbe and R E Coleman
The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia
Palliative Medicine, September 1, 2003; 17(6): 539 - 553.
[Abstract] [PDF]

Home page
 Ann OncolHome page
J.-J. Body, I. J. Diel, M. R. Lichinitser, E. D. Kreuser, W. Dornoff, V. A. Gorbunova, M. Budde, and B. Bergstrom
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
Ann. Onc., September 1, 2003; 14(9): 1399 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
J R Ross, Y Saunders, P M Edmonds, S Patel, K E Broadley, and S R D Johnston
Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer
BMJ, August 30, 2003; 327(7413): 469.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ibrahim, N. Scher, G. Williams, R. Sridhara, N. Li, G. Chen, J. Leighton, B. Booth, J. V. S. Gobburu, A. Rahman, et al.
Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases
Clin. Cancer Res., July 1, 2003; 9(7): 2394 - 2399.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur
U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid
Oncologist, October 1, 2002; 7(5): 393 - 400.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Wood, K. Bonjean, S. Ruetz, A. Bellahcene, L. Devy, J. M. Foidart, V. Castronovo, and J. R. Green
Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1055 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
P. Boasberg
Medical Oncology Analysis
Integr Cancer Ther, June 1, 2002; 1(2): 182 - 184.
[PDF]

Home page
 NEJMHome page
K. Arzoo, S. Sadeghi, and V. Pullarkat
Pamidronate for Bone Pain from Osteolytic Lesions in Langerhans'-Cell Histiocytosis
N. Engl. J. Med., July 19, 2001; 345(3): 225 - 225.
[Full Text] [PDF]

Home page
 JCOHome page
C. L. Shapiro, J. Manola, and M. Leboff
Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer
J. Clin. Oncol., July 15, 2001; 19(14): 3306 - 3311.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Ali, F. J. Esteva, G. Hortobagyi, H. Harvey, J. Seaman, R. Knight, L. Costa, and A. Lipton
Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients
J. Clin. Oncol., July 15, 2001; 19(14): 3434 - 3437.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Koizumi, M. Yoshimoto, F. Kasumi, and E. Ogata
What Do Breast Cancer Patients Benefit from Staging Bone Scintigraphy?
Jpn. J. Clin. Oncol., June 1, 2001; 31(6): 263 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
L Groff, E Zecca, F De Conno, C Brunelli, R Boffi, C Panzeri, M Cazzaniga, and C Ripamonti
The role of disodium pamidronate in the management of bone pain due to malignancy
Palliative Medicine, June 1, 2001; 15(4): 297 - 307.
[Abstract] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. S. MARKOWITZ, G. B. APPEL, P. L. FINE, A. Z. FENVES, N. R. LOON, S. JAGANNATH, J. A. KUHN, A. D. DRATCH, and V. D. D'AGATI
Collapsing Focal Segmental Glomerulosclerosis Following Treatment with High-Dose Pamidronate
J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1164 - 1172.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
R. J. Glynn and J. E. Buring
Counting Recurrent Events in Cancer Research
J Natl Cancer Inst, April 4, 2001; 93(7): 488 - 489.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. J. Cook and P. Major
Methodology for Treatment Evaluation in Patients With Cancer Metastatic to Bone
J Natl Cancer Inst, April 4, 2001; 93(7): 534 - 538.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Berenson, R. A. Vescio, L. S. Rosen, J. M. VonTeichert, M. Woo, R. Swift, A. Savage, E. Givant, M. Hupkes, H. Harvey, et al.
A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases
Clin. Cancer Res., March 1, 2001; 7(3): 478 - 485.
[Abstract] [Full Text]

Home page
 JCOHome page
T. Saarto, C. Blomqvist, P. Virkkunen, and I. Elomaa
Adjuvant Clodronate Treatment Does Not Reduce the Frequency of Skeletal Metastases in Node-Positive Breast Cancer Patients: 5-Year Results of a Randomized Controlled Trial
J. Clin. Oncol., January 1, 2001; 19(1): 10 - 17.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Trippoli, M. Vaiani, A. Messori, E. Tendi, and B. E. Hillner
Survival Gain in Cost-Effectiveness Studies
J. Clin. Oncol., September 18, 2000; 18(18): 3318 - 3318.
[Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, J. R. Berenson, N. A. Janjan, K. S. Albain, A. Lipton, G. Yee, J. S. Biermann, R. T. Chlebowski, and D. G. Pfister
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
J. Clin. Oncol., March 13, 2000; 18(6): 1378 - 1391.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. C. Weeks, C. E. Desch, and T. J. Smith
Pamidronate in Prevention of Bone Complications in Metastatic Breast Cancer: A Cost-Effectiveness Analysis
J. Clin. Oncol., January 1, 2000; 18(1): 72 - 72.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. H. Bilsky, E. Lis, J. Raizer, H. Lee, and P. Boland
The Diagnosis and Treatment of Metastatic Spinal Tumor
Oncologist, December 1, 1999; 4(6): 459 - 469.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
J. L. Abrahm and for the ACP-ASIM End-of-Life Care Consensus Panel
Management of Pain and Spinal Cord Compression in Patients with Advanced Cancer
Ann Intern Med, July 6, 1999; 131(1): 37 - 46.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Meli, L. Rausa, L. C. Panasci, V. Sandor, D. Melnychuk, C. D. Atkins, I. J. Diel, S. D. Costa, and M. Kaufmann
Clodronate in Metastatic Breast Cancer
N. Engl. J. Med., December 24, 1998; 339(26): 1940 - 1941.
[Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online